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Abstract
Plasmacytoid dendritic cells (pDCs) express the I-type lectin receptor Siglec-H and produce interferon a (IFNa), a critical anti-
viral cytokine during the acute phase of murine cytomegalovirus (MCMV) infection. The ligands and biological functions of
Siglec-H still remain incompletely defined in vivo. Thus, we generated a novel bacterial artificial chromosome (BAC)-
transgenic ‘‘pDCre’’ mouse which expresses Cre recombinase under the control of the Siglec-H promoter. By crossing these
mice with a Rosa26 reporter strain, a representative fraction of Siglec-H+ pDCs is terminally labeled with red fluorescent
protein (RFP). Interestingly, systemic MCMV infection of these mice causes the downregulation of Siglec-H surface
expression. This decline occurs in a TLR9- and MyD88-dependent manner. To elucidate the functional role of Siglec-H during
MCMV infection, we utilized a novel Siglec-H deficient mouse strain. In the absence of Siglec-H, the low infection rate of
pDCs with MCMV remained unchanged, and pDC activation was still intact. Strikingly, Siglec-H deficiency induced a
significant increase in serum IFNa levels following systemic MCMV infection. Although Siglec-H modulates anti-viral IFNa
production, the control of viral replication was unchanged in vivo. The novel mouse models will be valuable to shed further
light on pDC biology in future studies.
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Introduction
Dendritic cells (DCs) are a diverse population of professional
antigen-presenting cells that exhibit differences in both their
developmental origins and their functional properties. They are
distributed in different anatomical compartments such as the skin,
intestine, lung and lymphoid organs [1,2] where pathogen access is
prevalent. Two prominent murine DC sub-classes exist, conven-
tional DCs (cDCs) and plasmacytoid DCs (pDCs). The latter
subset of DCs expresses the I-type lectin receptor Siglec-H. pDCs
are implicated in immune tolerance [3–8], but are also known to
secrete large amounts of type I interferons (IFNs) in response to
viral infections [9,10].
Double stranded DNA viruses like cytomegalovirus (CMV) are
sensed by pDCs via the endosomal Toll-like receptor 9 (TLR9)
[11] and trigger strong IFNa responses which are critically
required for early viral control during MCMV infection [12,13].
To this end, Zucchini et al. have shown that pDCs are the main
early source of intracellular IFNa/b at 30–36 h post MCMV
infection [14]. Moreover, Swiecki et al. demonstrated that specific
pDC depletion in blood dendritic cell antigen 2 (BDCA2)-
diphtheria toxin receptor (DTR) transgenic mice (where ablation
of pDCs is mediated by diphtheria toxin) at 36 h post infection
(p.i.) resulted in impaired MCMV clearance with unhindered NK
cell expansion and function at later timepoints during infection
[13]. However, the precise receptors contributing to pDC-
mediated anti-viral defence remain incompletely defined.
Amongst the numerous receptors expressed by pDCs, antibody-
mediated crosslinking of Siglec-H was shown to negatively
influence IFNa production in response to CpG stimulation
[15,16]. This inhibitory regulation of IFNa by Siglec-H was
attributed to its association with the ITAM bearing adaptor
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molecule DAP-12 [16–19]. DAP-12 was postulated to recruit
inhibitory signalling mediators to dampen TLR-mediated activa-
tion. To address this hypothesis, Takagi et al. employed Siglec-
HDTR/DTR mice, where an IRES-DTR-EGFP cassette disrupts
the Siglec-H open reading frame, harbouring Siglec-H deficient
pDCs. HSV-1 infection of these mice induced a strong increase in
IFNa levels 6 h p.i. in vivo [20]. Additionally, Siglec-H was shown
to mediate endocytosis and cross-presentation of antigens suggest-
ing that it may contribute to capturing and delivering of viruses
and other pathogens to endosomal TLRs [18]. However, the
ligands of Siglec-H remain uncharacterized. Thus, Siglec-H
presents as an interesting immunomodulatory molecule pre-
dominantly expressed on pDCs, yet its in vivo function remains
incompletely understood.
To investigate this query, we generated a novel BAC-transgenic
Siglec-H reporter mouse (pDCre x RFP) and utilized Siglec-H2/2
mice as valuable genetic tools for studying Siglec-H and pDC
functions in MCMV infection in vivo. Using these novel mouse
strains we were able to show downregulation of Siglec-H on pDCs
upon MCMV inoculation. Siglec-H is, however, neither required
for MCMV infection nor for activation of pDCs. In contrast,
Siglec-H deficiency enhances IFNa production without influenc-
ing viral clearance.
Results
Genetic labeling of pDCs with RFP in pDCre x RFP
reporter mice
Since pDCs account for a minor fraction (,0.5%) of immune
cells in the spleen [21], we set out to develop a novel transgenic
mouse model where Cre recombinase is expressed under the
control of the Siglec-H promoter. Transgenic mice were crossed to
floxed RFP reporter mice [22], thereby terminally labeling Siglec-
H+ cells with RFP expression driven from the ubiquitous Rosa26
promoter (Figure S1). The resulting reporter mice are termed
pDCre x RFP from here on.
In order to determine the distribution of the reporter expression in
pDCre x RFP mice, we characterized cells from bone marrow (BM)
and spleen. Gating on individual cell populations revealed that Siglec
H+ pDCs were targeted most efficiently (Figure 1a, c). Notably, aside
of pDCs, we also observed RFP expression by a minor fraction of
Siglec-H2 cells which consisted of B-, T-, NK-, and NK-T cells from
both tested organs as well as splenic cDC and CD11cint BM cells
(Figure 1a–c). These results suggest that a small fraction of early
lymphoid progenitors actively transcribes the Siglec-H locus and is
fate-mapped in pDCre x RFP mice. As previously described, the
fluorescence intensity of the RFP reporter differs between cell types
and differentiation states and is not a reflection of incomplete
recombination [22]. We also found RFP expression by Siglec-H2
and Siglec-H+ common dendritic cell precursors (CDP) from in vitro
BM cultures of pDCre x RFP mice (Figure S2a).
Interestingly, we observed RFP expression only by 2365%
(BM) or 3068% (spleen) of pDCs (Figure 1a, c). Phenotypically
and functionally distinct pDC subsets have been reported in
humans and mice [23–27]. Thus, we performed a pDC surface
marker expression analysis including CCR9, Clec9A, B220, CD4,
CD8a, PDCA-1, and Ly-6C. When comparing RFP+ and RFP2
BM pDCs from pDCre x RFP mice, we observed minor
alterations in the MFIs of CCR9, Clec9A, B220, PDCA-1 and
Ly-6C and more RFP+ pDCs expressed CD4 (Figure 1d, top
panel). These differences were however not observed in peripheral
splenic pDCs with the exception of minor differences in the MFI
for CCR9 (Figure 1d, bottom panel). Recently a CD9+ pDC
subset with potent IFNa production capacities has been described
in the BM of mice [27]. We observed comparable targeting of both
CD9+ and CD92 pDCs in the pDCre x RFP mice (Figure S2b). As
we did not identify major phenotypic differences in the surface
marker expression of RFP+ versus RFP2 peripheral pDCs we also
wanted to confirm that they possess comparable cytokine
production capacities. To this end, we stimulated ex vivo purified
splenic RFP+ and RFP2 pDCs from pDCre x RFP mice with
different multiplicities of infection (MOI) of MCMV in vitro and
analyzed their TNFa and IFNa production. As shown in Figure 1e,
we did not observe significant differences in the production of the
key pro-inflammatory cytokines tested. Hence, given comparable
phenotypic and functional characteristics of peripheral RFP+ and
RFP2 pDCs, we report targeting of a representative fraction of
pDCs in the pDCre x RFP mice.
Siglec-H is downregulated upon MCMV infection in vivo
While studying RFP+ and RFP2 pDCs during MCMV
infection, we surprisingly observed downregulation of Siglec-H
expression by all pDCs upon MCMV infection in vivo (Figure 2a).
Thus, defining pDCs by Siglec-H surface expression is hampered.
To investigate the extent of Siglec-H downregulation on a per cell
basis we used our pDCre x RFP model. The advantage of this
model is that pDCs are still fate mapped by RFP expression even
after Siglec-H downregulation. Thus, we can accurately gate on
the targeted pDC fraction to investigate the consequences of
MCMV infection on pDCs. To exclude the non-pDCs targeted in
the pDCre x RFP mice a default channel for CD19, CD3e, and
NK1.1 was used. Furthermore, also CD11chi cDCs and MHCII2
CDP precursors [28,29] were gated out. Thus, in the final gate
only RFP+ pDCs remained. When comparing RFP+ pDCs from
mock treated and infected pDCre x RFP mice, we observed
Siglec-H downregulation upon infection (Figure 2b) with some
cells becoming even Siglec-H2. Therefore, Siglec-H surface
expression does not faithfully identify pDCs during an ongoing
MCMV infection because of its downregulation in vivo.
pDCs downregulate Siglec-H upon MCMV infection in a
TLR9- and MyD88-dependent manner
As we observed Siglec-H downregulation in vivo, we next sought
to study the mechanism. For this purpose we infected Flt3-L
Author Summary
Plasmacytoid dendritic cells (pDCs) represent a minor but
functionally important subset of dendritic cells. Siglec-H, a
surface receptor expressed on these cells, was shown to
modulate IFNa production, which in turn could influence
anti-viral functions in vivo. A potential role for Siglec-H as a
pathogen uptake receptor has also been postulated. Yet,
the precise in vivo function of this molecule in viral
replication remained unresolved. In this study, we adopt
two novel genetic mouse models to investigate Siglec-H
properties and ensuing function in vivo during murine
cytomegalovirus (MCMV) infection. By using novel reporter
mice which harbour permanently labeled Siglec-H+ pDCs,
we show that pDCs downregulate Siglec-H upon infection.
In an additional experimental system, in which pDCs lack
Siglec-H function, we demonstrate that this molecule is
not important for the regulation of MCMV pathogenicity.
In contrast, in the absence of Siglec-H more IFNa was
detectable in the serum. Importantly, this in vivo increase
in IFNa production does not influence viral replication. The
biological function of Siglec-H downregulation, also in the
context of other infections, requires further investigation.
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Figure 1. Characterization of the pDCre x RFP reporter line shows terminal targeting of pDCs. (A, B) BM and spleen cells from pDCre x
RFP mice were stained for Siglec-H, CD11c, MHCII, CD3e, CD19 and NK1.1 (A) Characterization of the reporter expression (RFP) by different cell types:
pDCs were gated as Siglec-H+, B cells as Siglec-H2 CD19+ CD3e2 NK1.12, T cells as Siglec-H2 CD192 CD3e+ NK1.12, NK-T cells as Siglec-H2 CD192
CD3e+ NK1.1+, and NK cells as Siglec-H2 CD192 CD3e2 CD11cint NK1.1+. FACS plots are representative for two individual experiments. (B)
Characterization of the RFP reporter expression by CD11chi MHCIIhi cDCs in spleen and CD11cint CD192 CD3e2 NK1.12 Siglec-H2 cells in BM. (C)
Quantification of (A, B) showing pooled data from 2 independent experiments using 4–5 mice/group. (D) Phenotypic comparison of pDC markers
expressed by RFP2 and RFP+ pDCs from BM (top panel) and spleen (bottom panel). pDCs were gated as Siglec-H+ CD11cint. Histogram overlays
display the isotype controls as dashed line, and the marker expression by RFP2 pDCs as grey filled histogram and by RFP+ pDCs as bold line. Data
shown are from one representative experiment out of two using 4 mice/group. (E) Splenic ex vivo pDCs were purified by FACS sorting from B16-Flt3L
treated pDCre x RFP mice and incubated with the indicated MOIs of MCMV in vitro. IFNa/TNFa concentrations were quantified in the supernatants
after 24 h incubation by ELISA or cytometric bead assay. Data shown are from one representative experiment out of two using a pool of 3 mice. The
differences between RFP2 and RFP+ pDCs were not significant as calculated by Students t-test. Data displayed in (D, E) are from one out of two
individual experiments with similar results. Data are displayed as mean 6 SD.
doi:10.1371/journal.ppat.1003648.g001
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differentiated bone marrow dendritic cells (BMDCs) with MCMV-
GFP and tracked Siglec-H expression in vitro over time (Figure 3a).
CD11c+Siglec-H2 DCs express virus encoded GFP starting from
3 h p.i., while both the frequencies of infected DCs and the GFP
expression levels progressively increase until 24 h p.i. Interesting-
ly, Siglec-H was downregulated on CD11c+ DCs starting from
6 h p.i. (Figure 3a, upper panel), whereas B220 expression
remained unaltered at different timepoints p.i. (Figure 3a, lower
panel). Interestingly, Siglec-H downmodulation precedes CD86
upregulation (Figure S3b). We next used sorted pDCs from
BMDC cultures and found that they also downregulated Siglec-H
upon MCMV infection or CpG-A treatment, underlining that
accessory cells are dispensable for this effect (Figure 3b). Since
pDCs sense MCMV mainly via TLR9 [11], we assessed whether
Siglec-H downregulation requires TLR9- and MyD88-dependent
signalling. Indeed, Siglec-H downregulation upon CpG-A or
MCMV treatment only occurred in wildtype (wt) but not in
TLR92/2 or MyD882/2 pDCs (Figure 3b). To test whether the
absence of Siglec-H downregulation in TLR92/2 and MyD882/2
pDCs was a consequence of impaired IFNa production, we
stimulated IFNAR2/2 pDCs. Although we found differences in
Siglec-H expression between mock treated wt and IFNAR2/2
pDCs (Figure 3c), pDCs still clearly downregulated Siglec-H in the
absence of type I IFN signalling upon MCMV infection or CpG-A
treatment (Figure 3c, d). Notably, we also observed Siglec-H
downregulation upon treatment with the TLR7 agonist R837
(data not shown). Thus, downregulation of Siglec-H is linked to
early intracellular activation signals which are dependent on
TLR9 and MyD88 signalling with only minor contribution of type
I IFN signalling.
Siglec-H does not modulate pDC infection
Siglec-H has been postulated as a pathogen uptake receptor
[16] and downmodulation of Siglec-H could prevent further
infection of pDCs. Thus, we wanted to test for the requirement of
Siglec-H for pDC infection/activation. To address this aim, we
compared differences in MCMV-GFP infection between sorted
Siglec-H2/2 and wt pDCs. We observed similiar low frequencies
of GFP+ wt and Siglec-H2/2 pDCs at 24 h p.i. (Figure 4a). Next
we quantified the viral titers from MCMV infected sorted pDCs
and cDCs from wt and Siglec-H2/2 BMDC cultures. Infected
cDCs from both groups showed high viral titers. As an additional
positive control we included mouse embryonic fibroblasts (MEFs)
infected with the same MOI. Wt and Siglec-H2/2 pDCs showed
basal levels of infection close to the detection limit (Figure 4b)
which is consistent with the literature describing pDCs as being
resistant to productive infection [12,30]. Additionally, MCMV
infected Siglec-H2/2 pDCs showed upregulation of the activation
marker CD86 albeit to a slightly lower extent than wt pDCs
(Figure 4c). Overall, Siglec-H deficiency on pDCs has no influence
on MCMV infection and pDC activation occurs in its absence.
Siglec-H2/2 mice produce significantly more IFNa during
the acute phase of MCMV infection
Siglec-H has a modulatory role in IFN signalling [16]. Thus, we
queried whether the absence of Siglec-H would influence anti-viral
immunity to MCMV infection in vivo. To address this aim, we used
BM from wt and the recently described Siglec-H2/2 mice [31] to
generate chimeric mice and confirmed efficient reconstitution
prior to infection (Figure 5a). Subsequently, mice were infected
with a low dose of 56104 plaque forming units (PFU) MCMV and
a kinetics of IFNa serum levels was performed. Our results show
that at both 1.5 and 3 days p.i. Siglec-H2/2 mice had significantly
higher IFNa serum levels compared with wt mice (Figure 5b). At
day 6 p.i., IFNa levels declined to wt levels in the Siglec-H2/2mice
(Figure 5b). Thus, we show that MCMV infected Siglec-H2/2mice
produce significantly more IFNa during the acute phase of MCMV
infection compared with wt mice.
MCMV infected Siglec-H2/2 and wt mice show similar NK
and CD8 T cell responses with equal viral load in primary
and secondary infected organs
Ablation of pDCs after low dose MCMV infection was shown to
enhance the viral load in the spleen, liver and salivary glands of
infected mice [13]. However, the functional contribution of Siglec-
Figure 2. Siglec-H is downregulated upon MCMV infection in vivo. pDCre x RFP mice were infected with 56104 PFU MCMV in vivo. (A)
Representative FACS plots show CD11c versus Siglec-H of live splenocytes at 36 h p.i. (B) Gating strategy showing exclusion of B-, T-, NK-T, and NK
cells by CD19, CD3e, NK1.1 in a default channel. RFP+ pDCs were gated as CD11cint B220+ MHCIIint to exclude MHCII2 DC precursors. Histogram
overlays show RFP+ pDCs from mock (bold line) and MCMV infected (dashed line) pDCre x RFP mice at 36 h p.i. Isotype staining is displayed as grey
histogram. Data are representative of 2 independent experiments using 4–5 mice with comparable results.
doi:10.1371/journal.ppat.1003648.g002
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H in viral clearance remained unknown. As NK cells and CD8+ T
cells are the major effector cells for MCMV clearance [32], we first
tested whether the increase in serum IFNa in infected Siglec-H2/2
mice influenced NK cell activation during the early phase of
infection. Both serum IFNc levels and CD69 expression on blood
NK cells were comparable between Siglec-H2/2 and wt mice
(Figure 6a, b). Furthermore we checked for KLRG-1 expression on
MCMV-specific Ly49H+ NK cells at day 8 p.i. and found a similar
activation status when comparing cells from wt and Siglec-H2/2
mice (Figure 6c, d).
We next analyzed MCMV-specific CD8+ T cells by H-2Db
M45 tetramer staining on day 8 p.i. Infected Siglec-H2/2 and wt
mice showed comparable frequencies (Figure 6e, f) and numbers
(Figure 6g) of tetramer+CD8+ T cells in the spleens of infected
mice. Also the IFNc production by CD8+ T cells from both groups
was comparable upon restimulation with M45 peptide (Figure 6h).
We finally examined the viral load in the spleen, liver and
salivary glands at day 3, 6 and 8 p.i. Importantly, viral clearance
in primary and secondary organs showed similar kinetics between
the two groups over time (Figure 6i). Infection peaked in the spleen
at day 3 and in the liver at day 6 with no significant differences due
to Siglec-H deficiency. Also infection in the salivary glands
reached the same level on day 6 and 8 p.i. Overall, our data show
that absence of Siglec-H does not alter the NK cell activation or
expansion of IFNc+ MCMV-specific CD8+ T cell generated in
response to infection. Additionally, viral clearance in the infected
organs remains unchanged irrespective of the presence or absence
of Siglec-H.
Figure 3. pDCs downregulate Siglec-H upon MCMV infection in a TLR9- and MyD88-dependent manner in vitro. Flt3-L derived total
BMDCs or CD11c+B220+ pDCs sorted from BMDC cultures were mock treated with PBS, CpG treated or MCMV infected at MOI 2 unless indicated
otherwise. (A) Representative FACS plots show Siglec-H expression and MCMV-GFP expression of BMDCs (upper panel). Representative histogram
plots display B220 expression on CD11c+ Siglec-H+ DCs at 0, 3, 6 and 24 h p.i. compared with mock treated controls (lower panel). (B) Representative
histogram plots display Siglec-H expression of sorted wt, TLR92/2 and MyD882/2 pDCs after stimulation or infection. (C) Representative histogram
plots display Siglec-H expression of sorted wt and IFNAR2/2 pDCs 24 h after infection or stimulation. (D) Quantification of the Siglec-H expression
from wt and IFNAR2/2 pDCs after MCMV infection relative to their respective mock controls. Data are from one of three individual experiments with
similar results. *p,0.05, ***p,0.001, Students t-test. (Gray bar = isotype control, gray dashed line =mock treatment and dark bold line = CpG-A
treatment or MCMV infection).
doi:10.1371/journal.ppat.1003648.g003
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Discussion
We have shown that Siglec-H expression is downregulated by
pDCs upon CpG-A or MCMV treatment in a MyD88- and
TLR9-dependent mechanism. This phenotypic change is observed
in vitro and in vivo. Since a downregulation of Siglec-H expression
complicates the identification of pDCs, we generated a novel
mouse model for fate mapping Siglec-H expression. In these mice
Siglec-H+ cells are terminally labeled irrespective of Siglec-H
downregulation at a later timepoint. The reporter expression in
the pDCre x RFP mice is the highest in pDCs (23–30%) when
gating on individual cell populations, as expected. Interestingly, we
also observed RFP expression in a minor fraction of B-, T-, NK-,
NK-T cells, as well as cDCs and common dendritic cell precursors
(CDPs). This might be explained by targeting of a Siglec-H+
precursor population as precursor-derived cells would be labeled
in our fate mapping approach even in the absence of Siglec-H
expression after terminal differentiation. In line with this
hypothesis, Siglec-H mRNA expression has been reported recently
for B cell progenitors, CDPs as well as common lymphoid
progenitors (CLPs) [33]. Furthermore, Satpathy et al. have shown
that a fraction of CDPs and particularly a subset of pre-cDCs
express Siglec-H at the surface [34]. However, Siglec-H expression
by these precursors does not necessarily correlate with pDC
differentiation potential and can be transient as a proportion of
Zbtb46+ Siglec-H+ precursors retains cDC differentiation potential
[34]. In addition, Swiecki et al. have demonstrated that a fraction
of cDCs are targeted in a Siglec-H GFP knock in approach [13].
Supporting these findings, we also report minor targeting of pro-
and pre-DCs in vitro using Flt3-L cultures of pDCre x RFP BM.
Interestingly, a substantial proportion of Siglec-H2 precursors is
fate mapped, which might indeed indicate that RFP reporter
expression precedes Siglec-H surface expression. It will be
interesting to test pDCre x RFP mice for possible targeting of
CLPs which can give rise to T-, NK-, NK-T and B cells [35–38].
To this end, we observed minor RFP reporter expression in early
CD3e2 and DN thymocytes (data not shown). It is unlikely that
BAC-related positional effects [39] are responsible for the
observed expression pattern in non-pDCs as we found similar
results in different pDCre founderlines generated from the same
BAC (data not shown). Thus, minor cDC, B cell, CDP, and
potential CLP targeting observed in the pDCre x RFP mice is
likely a reflection of early Siglec-H promoter activity in committed
precursors.
Interestingly, not all Siglec-H+ pDCs express the reporter in our
BAC transgenic model. For both humans and mice, phenotypi-
cally and functionally distinct pDC subsets have been described
[23–27]. However, the expression levels of the pDC surface
markers B220, Ly-6C, PDCA-1, CD8a, Clec9A, Siglec-H and
CD11c greatly overlapped between RFP+ and RFP2 pDCs in the
spleen. Cisse et al. demonstrated when comparing BMDC cultures
from wt and E2-22/2 mice, where pDC differentiation is blocked
at an early step, that Ly-6C is upregulated before PDCA-1, B220,
and Siglec-H [40]. Furthermore, CCR9 expression is also induced
late during pDC development. [24]. Thus, it appeared that RFP+
pDCs showed a slightly more mature phenotype in the BM of
pDCre x RFP mice. This might indicate that we are preferentially
targeting terminally differentiated CCR9+ pDCs and fewer Siglec-
H+ CCR92 B220low pDC precursors [24,41]. pDCs mainly
develop from Lin2c-Kitint/loFlt3+M-CSFR+ CDPs [28,29]. Re-
cently a progenitor with preferential pDC developmental potential
has been identified [42]. Yet, no pDC precursor with a sole pDC
differentiation potential has been found. Along this line, it would
be interesting to test whether RFP+ and RFP2 pDCs from the
pDCre x RFP mice originate from the same precursor population.
Despite the minor phenotypic differences observed in the BM, we
did not find a significant disparity in the IFNa or TNFa
production upon MCMV infection by peripheral RFP+ and
RFP2 pDCs indicating that we are targeting a representative
fraction of cytokine-competent pDCs rather than a distinct pDC
subset. We conclude that the pDCre x RFP mice are a suitable
model to study cytokine responses by pDCs upon virus challenge.
Figure 4. Siglec-H receptor does not play a role in pDC infection. Flt3-L derived CD11c+ B220+ pDCs and CD11c+ B2202 cDCs were sorted
from BMDC cultures of wt and Siglec-H2/2 mice. DCs were mock treated with PBS or MCMV-GFP infected at MOI 2. (A) Representative FACS plots
show Siglec-H expression and MCMV-GFP expression at 24 h p.i. (B) Quantification of the viral titers per 106 DCs or MEFs at 24 h p.i. (C)
Representative histogram plots of CD86 expression on wt and Siglec-H2/2 sorted pDCs (live cell gate) at 24 h p.i. (gray bar = isotype control, gray
dashed line =mock treatment, gray solid line = CpG-A treatment, dark bold line =MCMV infection). Data are from one of three individual experiments
with similar results. ns = not significant ***p,0.001, Students t-test.
doi:10.1371/journal.ppat.1003648.g004
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The injected BAC was chosen to cover approximately 100 kb
up- and downstream of the open reading frame to minimize
positional effects which are often observed with classical transgenic
mice [39,43]. However, missing regulatory elements required for
Siglec-H expression by all pDCs cannot be completely excluded. It
should be noted that many helpful transgenic mouse models
display a reporter activity that is lower than 100%. ([44,45] and
own unpublished data). This is a commonly observed phenom-
enon published for different promoters.
We found that Siglec-H downregulation on pDCs is an early
response to PAMP recognition in vitro and in vivo. Productive
infection of pDCs with MCMV is, however, low [30], possibly as a
consequence of the strong anti-viral response in these cells [12].
Thus, Siglec-H downregulation might be the consequence of pDC
activation primarily by means of viral PAMP transfer rather than
productive infection as previously shown for other viruses [46,47].
Because TLR7/9 ligation of pDCs induces a massive type I IFN
release, it was important to investigate whether type I IFN
signalling alone can induce Siglec-H downregulation. Interesting-
ly, Siglec-H expression by mock treated IFNAR2/2 BM-derived
pDCs was in general lower as compared with wt pDCs, suggesting
a link between IFNAR signalling and Siglec-H expression. Yet,
Siglec-H downregulation also occurred in the absence of IFNAR
upon MCMV infection. Thus, Siglec-H downregulation is not a
direct consequence of type I IFN signalling. Notably, also other
soluble factors released by infected wt DCs did not induce Siglec-
H downregulation on MyD882/2 pDCs in a transwell experiment
(data not shown), arguing for a pDC-intrinsic effect. We conclude
that the downregulation of Siglec-H is coupled to early intracel-
lular MyD88-dependent signalling events with minor contribu-
tions of the type I IFN signalling pathway.
Siglec-H was previously hypothesized to act as a pathogen
receptor although its natural ligands remain enigmatic [16].
However, our data suggest that MCMV infection of pDCs is not
affected by the absence of Siglec-H. Moreover, Siglec-H-deficient
mice are not protected from MCMV infection. Although Siglec-H
seems to be dispensable for infection, this does not exclude that it
might participate in virus uptake together with other endocytic
receptors with redundant functions.
We show that although Siglec-H is neither required for MCMV
replication nor for pDC activation, the absence of this endocytic
receptor leads to strongly increased IFNa serum levels in infected
mice. It has been previously shown that Siglec-H couples to the
adaptor protein DAP12, which negatively regulates type I
signalling [19,48]. DAP122/2 pDCs lack Siglec-H expression
and mount higher IFNa levels compared with wt pDCs [19,48]
similar to our findings for the Siglec-H2/2 mice. Interestingly, it
was demonstrated that DAP12-deficient pDCs also produce
increased amounts of IL-12 [19], suggesting that DAP12 may
regulate additional DC functions. Whether the absence of Siglec-
H or its downmodulation also affects DAP12 expression or
function warrants further investigation.
Siglec-H2/2 mice showed increased levels of serum IFNa
already 36 h p.i. with MCMV. pDCs are the main source of this
cytokine at this timepoint [13] and thus the absence of Siglec-H on
pDCs has direct consequences for the negative regulation of IFNa
signalling by these cells. This finding is consistent with published
data from Takagi et al. [20] who demonstrated a similar increase
in IFNa serum levels in Siglec-H deficient Siglec-H DTR/DTR mice
in the HSV-1 infection model. In contrast, we did not observe a
direct effect of these enhanced cytokine levels on the primary CD8
T cell response or NK cell activation and no differences in viral
clearance in spleen, liver or salivary glands during acute infection.
This is surprising given that Takagi et al. have shown that in the
absence of Siglec-H the HSV-1 specific CD8+ T cell response is
reduced and viral clearance is diminished [20]. The disparities
could be explained by the different mouse or infection model.
Alternatively, the wt IFNa serum levels upon MCMV infection
might already be saturating.
It is well established that type I IFN promotes anti-viral and
immunostimulatory responses [49–51]. However, the increased
IFNa levels in Siglec-H2/2 chimeric mice could also play a dual
Figure 5. IFNa serum levels are elevated in the absence of Siglec-H upon MCMV infection. Lethally irradiated CD45.1+ wt mice were
reconstituted with CD45.2+ wt or Siglec-H2/2 BM followed by infection with 56104 PFU of wt MCMV. (A) FACS plots show efficient donor
reconstitution in the blood eight weeks after BM transfer (upper panel). Siglec-H and B220 stainings of splenocytes confirm the lack of Siglec-H
expression in wt mice reconstituted with Siglec-H2/2 BM (lower panel). (B) The kinetics of serum IFNa levels 1.5, 3 and 6 days p.i. compared between
Siglec-H2/2 and wt mice, n = 4–5 mice/group. Data are from one of two individual experiments with similar results. ns = not significant ***p,0.001,
Students t-test.
doi:10.1371/journal.ppat.1003648.g005
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Figure 6. MCMV activates Ly49H+ NK cells and expands Ag-specific CD8+ T cells from Siglec-H2/2 and wt mice with similar viral
clearance in the primary and secondary organs. Siglec-H2/2 and wt chimeric mice were infected with 56104 PFU of wt MCMV or mock treated
with PBS. (A, B) IFNc serum concentrations were determined at 36 h p.i. and the MFI of CD69 expression on NK1.1+ blood NK cells was quantified by
flow cytometry. (C, D) Representative histogram overlays and quantification of KLRG-1 expression on splenic NK1.1+ Ly49H+ cells at day 8 p.i. (E)
Representative FACS plots for H-2Db M45 tetramer staining and CD62L expression among CD8+ splenocytes. (F, G) Quantification of frequencies and
absolute numbers of tetramer+ CD8+ T cells from the tetramer staining shown in (E). (H) Shows frequencies of IFNc+ cells among CD8+ T cells after
restimulation with the indicated concentrations of H-2Db M45 peptide. (I) Viral load was measured in the spleen, liver and salivary glands of MCMV
infected Siglec-H2/2 and wt mice at day 3, 6 and 8 p.i. Dashed line indicates the limit of detection. Data shown are pooled from 2–3 individual
experiments. **p,0.01 Students t-test, ns = not significant, nd = not detectable.
doi:10.1371/journal.ppat.1003648.g006
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role and induce negative immune regulation as recently described
[52,53]. Along this line, it would also be interesting to test how
Siglec-H2/2 mice control reactivation of the virus during chronic
infection.
In conclusion, we employed valuable novel mouse models to
terminally label a fraction of pDCs and to assess the functional role
of Siglec-H in vivo. Although Siglec-H is a well defined pDC
marker upon steady state conditions, our data suggest that caution
should be taken when using Siglec-H as a single marker to identify
pDCs upon MCMV infection. This might also apply for other
infection models. The mechanisms of TLR-induced Siglec-H
downregulation and increased IFNa secretion deserve future
investigations.
Material and Methods
Ethics statement
All animal experiments were performed in compliance with
the German animal protection law (TierSchG BGBl. I S. 1105;
25.05.1998). The mice were housed and handled in accordance
with good animal practice as defined by FELASA and the
national animal welfare body GV-SOLAS. All animal experi-
ments were approved by the Lower Saxony Committee on the
Ethics of Animal Experiments as well as the responsible state
office (Lower Saxony State Office of Consumer Protection and
Food Safety) under the permit numbers 33.9-42502-04-12/1020
and 33.9-42502-04-09/1785. All surgery was performed after
mice were euthanized and all efforts were made to minimize
suffering.
Generation of BAC transgenic pDCre mice
pDCre mice were generated using BAC technology [39,54]
with some modifications. We obtained a BAC encoding the
complete mouse Siglec-H gene locus (RP24-396N13) from the
BACPAC Resources Center at Children’s Hospital Oakland
Research Institute. As transgene, we created a Cre-IRES-cherry
construct containing a 39 polyA fragment (Figure S1). In
contrast to the published overlap PCR strategy [39], we used a
strategy based on homologous recombination: 1000 bp long
regions homologous to the 59 end before the ATG of exon 1 and
39 of exon 1 of Siglec-H were ligated to the transgene construct
via PCR-inserted AscI (59) or PmeI sites (39). The cherry
sequence was a kind gift from Dr. R. Tsien (UC San Diego).
The polyA fragment was amplified from the TOPO Tools SV40
pA 39 element kit (Promega) using primers adding a SpeI site 59
and a PmeI site 39. The Siglec-H containing BAC was
recombined using the pLD53.SC1 shuttle vector provided by
Dr. N. Heintz (The Rockefeller University, New York, NY), gel
purified and injected into the pronuclei of fertilized C57BL/6
oocytes. Multiple transgenic pDCre founder lines were estab-
lished and the pDCre x RFP line with the highest RFP
expression of 2365% in BM- and 3068% in splenic pDCs was
utilized in this paper. Within the RFP+ live cell population
pDCs constitute 6968% (BM) and 966% (spleen) of total cells.
Frequencies are given as mean 6 SD. pDCre mice were
genotyped by PCR using the following primers: (59-ttccatggcat-
gagagaaca-39) and (59-agtccagaagcccaaaggat-39). To analyze for
Cre-recombinase activity, the transgenic mice were bred to
reporter mice which carry a floxed td-RFP cassette downstream
of the ubiquitous Rosa26 promoter [22].
Generation of Siglec-H2/2 chimeric mice
Siglec-H2/2 BM was kindly provided by Dr. Lars Nitschke
(Erlangen, Germany). Siglec-H2/2 mice were generated by
the consortium for functional glycomics (http://www.
functionalglycomics.org/) [31] and provided by The Scripps
Research Institute (TSRI) (La Jolla, CA, USA). The construct
consisted of an FRT-flanked selection vector containing a
neomycin resistance gene and a single 39 loxP site was used in
the generation of this construct. The selection vector was
inserted downstream of exon 2 of the Siglec-H gene and a
second loxP site was inserted upstream of exon 1 via
homologous recombination. The mice carrying the construct
were then crossed with a Cre-recombinase transgenic mouse
thereby removing the majority of the coding sequences of
Siglec-H including those for the Ig-like domains and alterna-
tively spliced exon 2a.
For generating Siglec-H2/2 chimeric mice, CD45.1 mice
were obtained from Jackson laboratory, Maine, USA. CD45.1+
recipient mice were irradiated with 10 Gy and rested for 24 h
after radiation treatment. Irradiated mice were injected intra-
venously with 46106 BM cells from Siglec-H2/2 or C57BL/6J
control mice (both CD45.2 background). Following injection of
BM cells, mice were carefully monitored and reconstitution was
carried out for 6–8 weeks. Reconstitution efficiency was
examined by staining blood cells for CD45.1 vs. 45.2 after 6–
8 weeks. Siglec-H2/2 chimeric mice did not show any signs of
kidney dysfunction as assessed by serum creatinine measure-
ments.
Housing
pDCre x RFP reporter and C57BL/6 wildtype (wt) mice
(originally obtained from Jackson laboratories) were bred at the
animal facility of Twincore (Hannover, Germany) and at the
Helmholtz Centre for Infection Research (HZI, Braunschweig,
Germany). 8–12 week old mice were used for animal experiments.
All animals were housed under specific pathogen-free conditions.
Mice were sacrificed by CO2 asphyxiation as approved by
German animal welfare law. Every effort was made to minimize
any sort of suffering to the animals.
MCMV viral strains
The MCMV laboratory strains used were the BAC-derived wt
Smith Strain [55] and the recombinant Smith-based GFP strain
[56]. Both strains were kindly provided by Dr. Martin Messerle
from the Institute of Virology, Medical School, Hanover,
Germany. Virus strains were propagated in mouse embryonic
fibroblast (MEF) as described previously [57].
In vitro spin inoculations
16106 BMDCs/well were seeded in a 24well flat bottom plate.
FACS sorted Flt3-L derived pDCs were seeded at 16105 cells/well
in 96well flat bottom plate. DCs were incubated with MCMV
Smith-GFP or MCMV Smith (MOI 2), 1 mM CpG-A (ODN
2216) or PBS for 0, 3, 6 and 24 h. Infection of DCs was performed
by centrifugation at 1500 rpm for 30 min at 37uC. Following spin
infection, DCs were incubated at 37uC, 5% CO2 till harvested and
used for subsequent stainings.
In vitro stimulations of pDC populations from pDCre x
RFP mice
30,000 sorted SiglecH+RFP+, SiglecH+RFP2 pDCs were
seeded in a 96well U bottom plate and incubated with MCMV
(MOI 2 or 5), CpGA-2216 (0.1 mM, 1 mM) or mock infected with
PBS. Cells were incubated with appropriate stimuli for 24 h at
37uC, 5% CO2. Supernatants were collected and cytokines were
quantified as described below.
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In vivo systemic infection
Mice were infected intra-peritoneally with 56104 PFUs of wt
MCMV-Smith strain or mock infected with PBS. Mice were
carefully monitored over the course of infection and were
asymptomatic.
Quantification of infectious virus
Spleen, liver and salivary glands from sacrificed mice or cell
pellets from infected DCs/MEFs (modified protocol from Mathys
et al. [56]) were resuspended in MEM medium (Gibco Life
Technologies, Darmstadt, Germany). Homogenization was per-
formed by using a handheld homogenizer POLYTRON PT1200
(Fischer-Scientific GmbH, Schwerte, Germany). Organ homoge-
nates were then plated on a confluent layer of murine embryonic
fibroblasts (MEFs) and a serial dilution of 1021–1026 was
performed for each organ in duplicates. Infections of MEFs were
carried out in 24well flat bottom plates for 2 h at 37uC. After 2 h
of incubation the organ homogenates were decanted carefully and
a layer of methyl cellulose was overlayed to avoid infection by
residual free floating virus particles and permit only cell to cell
transfer of virus infection. After methyl cellulose overlay, the plates
were left at 37uC for 6 days until plaques developed.
Preparation of single cell suspensions for DC analysis
Spleens were cut into small pieces and digested in RPMI 1640
Glutamax medium (Gibco Life Technologies, Darmstadt, Ger-
many) supplemented with 10% FCS, 5 mM b-mercaptoethanol
(Gibco Life Technologies, Darmstadt, Germany), 100 U/ml
Penicilin/Streptomycin (Biochrom, Berlin, Germany), 1 mg/ml
Collagenase D (Roche diagnostics GmbH, Mannheim, Germany)
and 100 mg/ml DNase I (Roche diagnostics GmbH, Mannheim,
Germany). Digestion was stopped by addition of 10 mM EDTA
(pH 7.2). A single cell solution was prepared and red blood cells
were lyzed in RBC lysis buffer (150 mM NH4Cl, 10 mM
KHCO3, 0.1 mM EDTA). The isolated cells were counted by
trypan blue exclusion and adjusted to the same cell number for
FACS staining.
Preparation of BM and in vitro generation of BMDCs
BM cells were isolated from femurs and tibiae. In vitro
generation of fms-like tyrosine kinase 3 ligand (Flt3-L) driven
DCs from BM has been described previously [58]. 156106 BM
cells were seeded in 10 ml supplemented RPMI 1640 Glutamax
medium (Gibco Life Technologies, Darmstadt, Germany) con-
taining Flt3-L (self-made from CHO Flt3-L FLAG cells [58]). Cells
were cultured for 9 days at 37uC, 5% CO2 before stimulation
experiments were performed. Flt3-L producing CHO cells were
generated by Dr. Nicos Nicola and kindly provided by Dr. Karen
Murphy, WEHI, Melbourne, Australia.
Stainings for flow cytometric analysis
Cells were washed in PBS and stained with the live/dead fixable
aqua dead cell stain kit (Invitrogen, Life Technologies GmbH,
Darmstadt, Germany) to exclude dead cells. Cells were washed
with PBS and incubated in FACS buffer (0.25% BSA/2 mM
EDTA in PBS) containing Fc-block (CD16/32, 2.4G2) for 10 min
on ice. Cells were stained with fluorescently labeled antibodies (Ab)
for cell surface markers. Stainings were performed for 20 to
30 min on ice. Cells were fixed with 2% PFA in PBS for 20 min
on ice. Where indicated, cells were washed with permeabilisation
buffer (0.25% BSA/2 mM EDTA/0.5% saponin in PBS) and
stained intracellularly for IFNc 20 min on ice. Samples were
stored at +4uC, acquired on a LSRII flow cytometer (BD
Bioscience GmbH, Heidelberg, Germany), and analyzed using
FlowJo software (Tree Star, Inc. Ashland, USA). Single stains and
fluorescence minus one controls were used for accurate gating and
compensation. Non-specific binding was estimated by isotype
controls and cellular aggregates were excluded by SSC-W.
Antibodies
All antibodies were purchased from eBioscience (Frankfurt,
Germany) if not stated otherwise.
The following fluorochrome labeled anti-mouse antibodies were
used:
For pDCs after in vitro infection: B220 (RA3-6B2), CD11c
(N418), CD86 (GL1), MHCII (AF6-120.1) and Siglec-H (440c).
For pDC markers: CD11c (N418), B220 (RA3-6B2), PDCA-1
(eBio927), Ly-6C (HK1.4), CD9 (MZ3), CCR9 (242503, R&D),
Clec9A (7H11, Miltenyi), Siglec-H (440c), CD4 (GK1.5) and
CD8a (53–6.7). For characterization stainings of spleen and BM
from pDCre x RFP mice: NK1.1 (PK136), CD3e (145-2C11),
CD19 (eBio1D3), CD11c (N418), Siglec-H (440c), MHCII (M5/
114.15.2).
For blood NK cells: NK 1.1 (PK136), Ly49H (3D10), CD69
(H1.2F3), and CD3e (145-2C11). For peptide restimulated
splenocytes: CD8a (53–6.7), CD62L (MEL-14), CD44 (IM7),
KLRG1 (2F1) extracellularly and IFNc (XMG1.2) intracellularly.
H-2Db M45 tetramer (PE-conjugated, a kind gift from Dr. Luka
Cicin-Sain) stainings were performed in a 96well U bottom plate
at 26106 splenocytes/well after surface staining for 1 h on ice.
Cell sorting
Cell sorting was carried out at the Cell Sorting Core facility of
the Hannover Medical School using the FACSAria (BD) or XDP
MoFlow (Beckman Coulter) FACS sorting machines. pDCs were
sorted as CD11cint Siglec-H+ NK1.12 CD192 CD3e2 after
enrichment from spleens of B16-Flt3L treated pDCre x RFP mice
using Optiprep gradient (Axis Shield, Oslo, Norway). Cells were
sorted with a 100 mm nozzle, collected in filtered FCS and kept on
ice till use. The purity of the sorted cells was determined for each
sample and was .95–98%.
T cell restimulation assay
T cell restimulation assay was performed in a 96well U bottom
plate. 26106 splenocytes from mock treated and day 8 MCMV
infected wiltype and Siglec-H2/2 chimeric mice were incubated in
the presence of 3 mg/ml brefeldin A (eBioscience, Frankfurt,
Germany) and M45 H-2Db peptide (HGIRNASFI, Pro-Immune,
Oxford) at 1 mg/ml, 1 ng/ml and 1 pg/ml final concentration or
without peptide at 37 C, 5% CO2 for 4 h.
Cytokine quantification
Supernatants from stimulated pDCs and serum samples from
infected mice were used to determine cytokine concentration
by ELISA or by FlowCytomix bead assay. For the IFNa
ELISA, maxisorp plates (Nunc, Denmark) were coated with
anti-mouse IFNa (clone: RMMA-1) and blocked using 1% BSA
in PBS. Samples were incubated overnight at 4uC. A poly-
clonal anti-IFNa antibody from rabbit (both IFNa antibodies
from PBL Interferon Source, NJ, USA) and a HRP conjugated
anti-rabbit IgG (H+L) antibody (Dianova, Hamburg, Germany)
were used as secondary reagent. HRP activity was detected by
BD OptEIA solutionA/B (BD Bioscience GmbH, Heidelberg,
Germany) and quantified at 570/450 nm. TNFa and IFNc
were quantified by a FlowCytomix bead assay (eBioscience,
Frankfurt, Germany).
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Statistics
The Students t-test was used to calculate the statistically
significant differences between samples. A value for p,0.05 was
considered significant indicated by an asterisk sign: (*) for P,0.05,
(**) for P,0.01 and (***) for P,0.001.
Supporting Information
Figure S1 Construct design of the pDCre mouse by
targeting the Siglec-H promoter with BAC gene technol-
ogy. Shown here is the design of the Siglec-H BAC construct
displaying the recombination site within the Siglec-H exon 1 locus.
Mice carrying this construct expressed Cre recombinase under the
influence of the Siglec-H promoter and were further bred to floxed
RFP reporter utilizing the ubiquitous Rosa 26 promoter to
generate the pDCre x RFP reporter mice.
(TIF)
Figure S2 Reporter expression in early dendritic cell
precursors and CD9+ pDC. (A) Shows an in vitro CDP
differentiation assay from CFSE labeled BM from pDCre x RFP
mice or littermates analyzed on day 3 of Flt3-L culture based on a
protocol from Naik et al. [28]. Ly-6G, MHCII, CD19, and
CD127 were excluded in a default channel. Pro-DCs were gated
as CFSElow CD11c2 and pre-DCs as CFSElow CD11c+.
Representative FACS plots showing Siglec-H (or isotype control)
staining versus RFP reporter expression from one out of two
independent experiments. (B) CD9 expression by BM pDCs from
pDCre x RFP mice or littermates gated as Siglec-H+ CD11cint
from one out of two independent experiments.
(TIF)
Figure S3 Co-expression of CD86 versus Siglec-H on
BMDCs at 0, 3, 6 and 24 h p.i. Flt3-L derived mixed BMDCs
were MCMV-GFP infected at MOI 2. Cells were gated on live
CD11c+ GFP2 and CD11c+ GFP+ DCs. (A) Gating strategy. (B)
Co-expression of Siglec-H versus CD86 expression. Results are
representative for 3 independent experiments.
(TIF)
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